Presenter

Dominique Semon

Private Equity Chief Investment Officer, Merlin BioMed Group

Mr. Semon started his career in 1983 at Biogen in Geneva, Switzerland, where he created and managed the company’s DNA sequencing laboratory. While at Biogen, he participated in various R&D projects, including hepatitis B vaccine, beta-interferon and tumor necrosis factor and has written numerous articles that have appeared in well-recognized scientific publications. In 1989, Mr. Semon joined Citibank Global Asset Management in Zurich, Switzerland as a management trainee and served in various management positions in Zurich and New York until 1992. From 1992 to 1998, Mr. Semon managed a healthcare private equity portfolio at New York Life Insurance company, where his responsibilities included all aspects of private equity investing. From early 1998 until March 2001, Mr. Semon was Head of Health Care Private Capital Markets Group at Robertson Stephens, a leading investment bank, where he had responsibility for all aspects of private placement transactions, including origination, due diligence and marketing. Over a three-year period, he raised over $1 billion of capital in more than 20 transactions, including sale of preferred stock and PIPE offerings to the U.S. and European institutional market. Mr. Semon received a License es Science in Molecular Biology from the University of Neuchatel, Switzerland and a M.A. in Economics from New York University. He is a Chartered Financial Analyst (CFA).

Become a TIGER 21 Member

Success is where we begin.
Submit Inquiry

Become a TIGER 21 Chair

TIGER 21 Chairs have achieved the kind of success most people can only imagine. Now is your opportunity to do even more – for you and for others.
Submit Inquiry